Sugi Predict

Sugi Predict / Compounds / SCHEMBL2348997

SCHEMBL2348997

SCHEMBL2348997

COC(=O)C1CCC(CBr)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.41
▸ GAA P10253 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ PPM1B O75688 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ PPP1CC P36873 1/20 0.40
▸ HTT P42858 1/20 0.39
▸ CHRNB2 P17787 2/20 0.38
▸ CHRNA4 P43681 2/20 0.38
▸ CHRNB4 P30926 1/20 0.38
▸ CHRNA3 P32297 1/20 0.38
▸ CHRNA7 P36544 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ HPGD P15428 2/20 0.37
▸ MAPT P10636 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31455471 1.00 TP53 (0.43) TP53ALDH1A1GAASMN1; SMN2PPM1B
SCHEMBL6616808 1.00 TP53 (0.43) TP53ALDH1A1GAASMN1; SMN2PPM1B
SCHEMBL1660434 0.88 CHRNB2 (0.40) TP53ALDH1A1GAASMN1; SMN2PPM1B
SCHEMBL1660432 0.88 CHRNB2 (0.40) TP53ALDH1A1GAASMN1; SMN2PPM1B
SCHEMBL15200264 0.83 GAA (0.47) TP53ALDH1A1GAASMN1; SMN2PPM1B
SCHEMBL5543322 0.83 GAA (0.47) TP53ALDH1A1GAASMN1; SMN2PPM1B
SCHEMBL17118123 0.83 TP53 (0.46) TP53ALDH1A1GAASMN1; SMN2PPM1B
SCHEMBL14305169 0.83 TP53 (0.46) TP53ALDH1A1GAASMN1; SMN2PPM1B
SCHEMBL358775 0.83 GAA (0.47) TP53ALDH1A1GAASMN1; SMN2PPM1B
SCHEMBL244740 0.82 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709722-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 — — EP disclosed
WO-2025059577-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS ATAVISTIK BIO, INC. (US) 2025-03-20 — — WO disclosed
US-20250059183-A1 PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST SHANGHAI VISONPHARMA CO., LTD. (CN) 2025-02-20 — — US disclosed
WO-2024233547-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2024-11-14 — — WO disclosed
EP-4446323-A1 PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST Shanghai Visonpharma Co., Ltd. (CN) 2024-10-16 — — EP disclosed
WO-2023104165-A1 PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST 上海维申医药有限公司 2023-06-15 — — WO disclosed
EP-3969458-A1 CHEMICAL COMPOUNDS Boragen, Inc. (US) 2022-03-23 — — EP disclosed
WO-2021111475-A1 PROCESS FOR PREPARING TRANEXAMIC ACID KAWMAN PHARMA PRIVATE LIMITED (IN) 2021-06-10 — — WO disclosed
US-9682978-B2 2,6,7 substituted purines as HDM2 inhibitors MERCK SHARP & DOHME CORP. (US) 2017-06-20 — — US disclosed
US-20150368247-A1 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-12-24 — — US disclosed
WO-2014123882-A1 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-14 — — WO disclosed
US-20140206660-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof TRANSTECH PHARMA, LLC (US) 2014-07-24 — — US disclosed
US-8741900-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, LLC (US) 2014-06-03 — — US disclosed
US-20130197007-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof TRANSTECH PHARMA, INC. (US) 2013-08-01 — — US disclosed
US-8431575-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, INC. (US) 2013-04-30 — — US disclosed
EP-2536283-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TransTech Pharma, Inc (US) 2012-12-26 — — EP disclosed
US-20110230458-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA, INC. (US) 2011-09-22 — — US disclosed
WO-2011103091-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA, INC. (US) 2011-08-25 — — WO disclosed
EP-0683781-B1 NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE METABASIS THERAPEUTICS INC (US) 2004-04-21 — — EP disclosed
US-5731432-A Inhibitors of adenosine monophosphate deaminase GENSIA SICOR INC. (US) 1998-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368247-A1 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS DDX21, NSUN2, DHX29 TP53 39/4885ALDH1A1 1988/4885GAA 3610/4885
US-20140206660-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof AGER, NOD2, GPBAR1 TP53 1286/4885ALDH1A1 315/4885GAA 43/4885
US-20110230458-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF AGER, PSEN2, PSEN1 TP53 1304/4885ALDH1A1 461/4885GAA 27/4885
US-20130197007-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof AGER, PSEN2, PSEN1 TP53 1304/4885ALDH1A1 461/4885GAA 27/4885
US-20250059183-A1 PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST TLR7, TLR8, TLR1 TP53 493/4885ALDH1A1 2284/4885GAA 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.